At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Mar 3, 2026 at 07:00 ET
Passage Bio reported Q4 and full-year 2025 financial results, highlighting clinical progress in its upliFT-D trial for frontotemporal dementia, including enrollment in new cohorts and a cash runway extending into Q1 2027. While R&D and net loss decreased year-over-year, no revenue was generated as the company remains pre-revenue with ongoing clinical development.
- Cash and cash equivalents were $46.3 million as of December 31, 2025, down from $76.8 million in 2024.
- R&D expenses decreased to $23.3 million in 2025 from $40.2 million in 2024.
- Net loss narrowed to $45.5 million in 2025 from $64.8 million in 2024.
- Enrolled first three FTD-GRN patients in Cohort 3 and treated first FTD-C9orf72 patient in Cohort 4 of the upliFT-D study.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access